Impairment was greater in patients than controls, but declines in some cognitive domains abated over time.
Cancer-related cognitive impairment has long been described in association with breast cancer therapy, and patients often express feeling “less sharp and more forgetful” than before the breast cancer diagnosis. Investigators in France report neurocognitive findings for 276 patients with stage I–III breast cancer who were evaluated before treatment and 1 and 2 years after the diagnosis of breast cancer. A group of 135 age-matched healthy controls underwent the same evaluations.
A battery of neuropsychological tests were used to assess five cognitive domains, including episodic memory, working memory, information processing speed, attention, and executive function. Participants also self-reported cognitive difficulties and were evaluated for a…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)